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Abstract
The Wilms tumor 1 (WT1)-associated protein (WTAP) is upregulated in many tumors, including, acute myeloid
leukemia (AML), where it plays an oncogenic role by interacting with different proteins involved in RNA processing
and cell proliferation. In addition, WTAP is also a regulator of the nuclear complex required for the deposition of N6-
methyladenosine (m6A) into mRNAs, containing the METTL3 methyltransferase. However, it is not clear if WTAP may
have m6A-independent regulatory functions that might contribute to its oncogenic role. Here, we show that both
knockdown and overexpression of METTL3 protein results in WTAP protein upregulation, indicating that METTL3 levels
are critical for WTAP protein homeostasis. However, we show that WTAP upregulation is not sufficient to promote cell
proliferation in the absence of a functional METTL3. Therein, these data indicate that the reported oncogenic function
of WTAP is strictly connected to a functional m6A methylation complex.
Introduction
N6-methyladenosine (m6A) is the most abundant
internal chemical modification in eukaryotic mRNA and it
can control any aspect of mRNA post-transcriptional
regulation1. In mammals, the writer of m6A is a nuclear
multicomponent complex composed of two
methyltransferase-like proteins, METTL3 and METTL14,
and the regulatory proteins Wilms tumor 1-associated
protein (WTAP), vir like m6A methyltransferase asso-
ciated (VIRMA, also known as KIAA1429), RNA-binding
motif protein 15 (RBM15) and zinc finger CCCH-type
containing 13 (ZC3H13)1, 2. METTL3 is the sole catalytic
component of the complex while METTL14 functions in
structural stabilization and RNA substrate recognition3–5.
More recently, the human U6 snRNA m6A methyl-
transferase METTL16 has been shown to target intronic
regions of pre-mRNAs and lncRNAs6, 7. Removal of m6A
from transcripts occurs predominantly in the nucleus and
requires the activity of the alkB homologue 5 protein
(ALKBH5) and fat mass and obesity-associated protein
(FTO)1. Several proteins, in both nucleus and cytoplasm,
can read m6A modification and, eventually, regulate dif-
ferent phases of mRNA expression8. In particular, pro-
teins containing the YTH domain were the first to be
identified as m6A-specific “readers”. Notably, METTL3
itself can switch from writer to reader by moving in the
cytoplasm where it can regulate the translation of specific
mRNAs by direct binding to RNA and recruitment of
eIF39, 10.
The WTAP protein has been recently described as an
oncogenic protein in different cancers, including acute
myeloid leukemia (AML)11. WTAP was initially identified
as an interactor of the Wilms Tumor-1 (WT-1) protein12,
a zinc-finger protein that can act as both transcriptional
and splicing regulator. Later on, WTAP was shown to
form stable interactions with the Hakai protein (also
known as CBLL1), a C3HC4-type RING finger containing
E3 ubiquitin ligase whose expression is correlated to cell
proliferation and tumorigenesis13, and different proteins
involved in regulation of RNA processing and translation,
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including METTL314. Interestingly, even if a large pro-
portion of mRNAs associated with WTAP is also bound
by METTL3, there are many mRNAs that are specifically
associated with only one of the two proteins and upon
knockdown only half of the misregulated genes are in
common between the two factors15. Moreover, it has been
proposed that WTAP form a stable complex with Virma,
Hakai, Rbm15, and Zc3h13 (referred to as MACOM,
m6A-METTL-associated complex) that acts beyond m6A
methylation2. Thus, it is not clear if WTAP may have
independent regulatory functions from the m6A mod-
ification complex that might contribute to its oncogenic
role.
Here, we show that both the knockdown and over-
expression of METTL3 protein results in WTAP upre-
gulation, indicating that METTL3 levels are critical for
WTAP protein homeostasis. In particular, we demon-
strate that METTL3 levels may regulate WTAP expres-
sion at multiple levels by direct and indirect mechanisms
that include mRNA translation and stability. However, we
show that WTAP upregulation has on oncogenic effect
only in the presence of a functional METTL3.
Results and discussion
To get insight into a potential role of the m6A methy-
lation complex in AML, we first analyzed the expression
of its components in a variety of AML subtypes, normal
hematopoietic progenitor cells and mature myeloid cells
(data from GEO and the Cancer Genome Atlas databases,
TCGA). METTL3 and METTL14 mRNAs are sig-
nificantly up-regulated in a high percentage of different
AML FAB subtypes (the French–American–British clas-
sification of AML) compared to mature myeloid cells,
while both genes are highly expressed in CD34+ pro-
genitor cells (Fig. 1a and Supplemental Figure S1). The
lack of significance in M6 and M7 AMLs is very likely due
to the small number of samples. Moreover, it has been
reported that both METTL3 and METTL14 are also
highly expressed in AML compared to other cancers16.
While our studies were in progress, different independent
studies reported similar results showing a specific up-
regulation of METTL3 and METTL14 in AML cells and a
critical role for these proteins in AML cells survival and
differentiation17–20. On the other hand, we observed low
expression of WTAP mRNA despite the high levels of
WTAP protein reported in AML11.
By analyzing published m6A-seq and m6A-CLIP
experiments performed in different cell lines17, 21–23,
including the AML cell line MonoMac6, we observed that
WTAP mRNA is generally m6A methylated in exon 6 and
in exon 8 (Fig. 1b). Furthermore, published PAR-CLIP
data revealed binding of METTL3 within the m6A peak in
the exon 8 of WTAP mRNA (Fig. 1b)22. We checked for
METTL3, METTL14 and WTAP localization in several
AML cell lines, and in all of them we detected METTL3
mislocalization in the cytoplasm while the other compo-
nents of the m6A methylation complex were pre-
dominantly localized in the nuclear fraction (Fig. 2a).
Therein, in view of these results, we hypothesized that
METTL3 might contribute to the WTAP aberrant up-
regulation observed in AML.
By using K562 leukemia cells stably expressing a dox-
ycycline (dox) inducible METTL3 or METTL3 catalytic
inactive mutant (aa395–398, DPPW→APPA, METTL3
APPA), we showed that METTL3 overexpression (48 h
dox) resulted in increased levels of WTAP protein with-
out concomitant increase in WTAP mRNA levels (Fig. 2b,
c). Notably, METTL3 positively controls WTAP protein
levels regardless its catalytic activity, similar to what has
been shown for the translational control mediated by
cytoplasmic METTL3 in lung cancer9.
Binding of METTL3 and METTL3 APPA to WTAP
mRNA in cytoplasm of K562 cells was confirmed by CLIP
experiments using stable cell lines carrying inducible
FLAG-tagged expression cassettes (Fig. 2d). The METTL3
cytoplasmic mRNA target encoding for TAZ9 was utilized
as positive control. Altogether these data showed that
WTAP mRNA is m6A methylated and bound by cyto-
plasmic METTL3.
To analyze if the observed phenotype was specific of
AML cells, we transfected HeLa cells with a plasmid for
transient expression of a FLAG-tagged WTAP construct
containing only WTAP coding sequence together with
plasmids expressing a GFP control, METTL3 or METTL3
APPA (Fig. 3a, b). Also in this case, we observed increased
expression of FLAG-WTAP protein without concomitant
increase of FLAG-WTAP mRNA expression.
It has been recently shown that METTL3 can bind m6A
containing mRNAs10. We therefore examined whether
m6A modifications in WTAP mRNA are necessary for
METTL3 binding. We transfected a FLAG-tagged WTAP
construct with a deletion in the region of exon 8 (FLAG-
WTAP_Δ8), containing the m6A modifications, together
with plasmids for METTL3 expression or control GFP
(Supplementary Figure S2). The construct was already
devoid of 5′- and 3′-UTR. Notably, we still observed
increased WTAP protein levels and binding of METTL3
protein to WTAP mRNA. Moreover, binding of METTL3
and METTL3 APPA to FLAG-WRAP_Δ8 in cytoplasm of
transfected cells was confirmed by CLIP experiments.
These findings indicate that m6A modifications in WTAP
mRNA are not required for METTL3 association.
In order to understand if the increase of WTAP protein
depends on translation or protein stabilization, we per-
formed overexpression of METTL3 protein in the pre-
sence of the translation elongation inhibitor
cycloheximide (Fig. 3c). Thus, we co-transfected HeLa
cells with the FLAG-tagged WTAP construct (see above)
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Fig. 1 METTL3 and METTL14 are upregulated in AML. a METTL3, METTL14, and WTAP expression in AML of different FAB subtypes (in blue), M0 (n
= 15), M1 (n= 43), M2 (n= 42), M3 (n= 17), M4 (n= 36), M5 (n= 22), M6 (n= 3), and M7 (n= 3); normal CD34+ hematopoietic progenitors (n= 22)
and mature myeloid cells (in gray), normal CD14+ monocytes (n= 34) and polymorphonuclear leukocytes (PMNs, n= 30). Data were obtained from
public microarray repositories. The box plots illustrate the distribution of expression values of the mean of all probes present in the microarray for
indicated gene; the central solid line indicates the median; the limits of the box show the upper and lower percentiles. *p < 0.001 calculated on AML
and CD34+ with respect to mature myeloid cells. Values for single probes are represented in Supplemental Figure S1. b Analysis of m6A peak and
METTL3 binding in WTAP mRNA using published m6A CLIP (GSM1828594, GSM1828596, GSM2300426), METTL3 PAR-CLIP (GSM1135006 and
GSM1135007) and m6A-seq (GSM2010455, GSM2010456) data, the bars in the m6A CLIP lane indicate m6A sites
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together with a plasmid expressing the wild type METTL3
protein, METTL3 APPA or control GFP. After 48 h from
transfection we treated cells with cycloheximide for 4 h
(+CHX). We used non-treated cells as control cells
(−CHX). Properly occurred translational block was ver-
ified by checking the level of p27 protein, a well-known
short half-life protein in proliferating cells24. In contrast,
Actinin (ACTN1) protein levels were found to be con-
stant throughout the experiment, thus it was utilized as
endogenous control. Interestingly, we observed that after
cycloheximide treatment WTAP protein decreased at the
same levels in cells expressing METTL3 constructs and
control GFP (Fig. 3c), indicating that the observed
increased of WTAP in the control cells is not merely due
to protein stabilization.
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Fig. 3 METTL3 regulates WTAP protein levels in HeLa. a Western
blot analysis of HeLa cells transfected with a plasmid for transient
expression of a FLAG-tagged WTAP together with plasmids expressing
a GFP control, METTL3 or METTL3 APPA. b qRT-PCR analysis of FLAG-
WTAP mRNA in the same cells. c Representative Western blot analysis
of HeLa cells transfected with a plasmid for transient expression of a
FLAG-tagged WTAP together with a plasmid expressing the wild type
METTL3 protein, METTL3 APPA or control GFP and treated with
cycloheximide for 4 h. Higher exposure (HE) of FLAG-WTAP in GFP
transfected cells is shown. Data are presented as ±SEM from three
independent experiments
Fig. 2 METTL3 is mislocalized to cytoplasm in AML and regulates
WTAP expression. aWestern blot analysis of METTL3 and METTL14 in
nuclear, “N”, and cytoplasmic, “C”, fractions of different myeloid
leukemia cell lines. WTAP and GAPDH were utilized as nuclear and
cytoplasmic controls, respectively. b Western blot analysis of WTAP
and METTL3 expression in K562 cells overexpressing METTL3 and
METTL3 catalytic inactive mutant (METTL3 APPA). Densitometric
analysis of WTAP/ACTN1 ratio from replicates (N= 5) is shown below
with s.e.m. c qRT-PCR analysis of WTAP mRNA in the same cells.
d Upper panel, qRT-PCR of CLIP experiments performed with FLAG
METTL3 and FLAG-METTL3 APPA from cytoplasmic extract of K562
cells. Lower panel, representative Western blot analysis of FLAG-
tagged proteins. Data are presented as ±SEM from three independent
experiments. *p < 0.05
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In view of the reported activity of cytoplasmic METTL3
on mRNA translation9, we performed a polysome profil-
ing by sucrose gradient centrifugation from cytoplasmic
extracts prepared from control (GFP) or METTL3
(METTL3 and METTL3-APPA) stably expressing K562
cells and transiently transfected HeLa cells (Figs. 4 and 5).
Similar to what we observed on K562, in HeLa cells the
endogenous WTAP protein displayed an increase
expression in both METTL3 and METTL3 APPA over-
expression compared to GFP (Fig. 5). Again, the protein
increase is not accompanied by WTAP mRNA upregu-
lation. Then, we extracted RNA from the fractions adding
an equal amount of RNA spike-in to each of them for
normalization and analyzed WTAP mRNA distribution in
pooled fractions representing heavy-polysomes (fractions
1–3), light-polysomes (fractions 4–6), 80S (fractions 7–9)
and free-mRNAs (fractions 10–12). Then, we performed
qRT-PCR on WTAP and a control mRNA, ActB (Figs. 4a,
b and 5c, d). Importantly, upon overexpression of
METTL3 and METTL3-APPA we observed an increase of
WTAP mRNA in the polysomal fractions associated with
a decrease from the free RNA fractions. Moreover, ana-
lysis by Western blot revealed that, similarly to the
translation initiation factor eIF3a, METTL3 was detected
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Fig. 4 METTL3 associates with translating ribosomes and regulates WTAP mRNA translation in K562 cells. a Representative polysome profiles
performed with K562 cytoplasmic extract. b ActB and WTAP mRNA distribution across the gradient was evaluated in each fraction by real-time qPCR.
c Polysome-fractionated samples analyzed by western blot using the indicated antibodies. Data are presented as ±SEM from three independent
experiments. *p < 0.05
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Fig. 5 METTL3 associates with translating ribosomes and regulates WTAP mRNA translation in HeLa cells. a Western blot analysis of WTAP
expression in HeLa cells transfected with plasmids for ectopic expression of METTL3, METTL3 APPA, and control GFP. b qRT-PCR analysis of WTAP
mRNA in the same cells. c Representative polysome profiles performed on the same cells. d ActB and WTAP mRNA distribution across the gradient
was evaluated in each fraction by real-time qPCR as described in Supplementary Methods. e Polysome-fractionated samples analyzed by western
blot using the indicated antibodies. Data are presented as ±SEM from three independent experiments. *p < 0.05
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with 80S and light polysomal fractions (Figs. 4c and 5e).
Thus, we can conclude that METTL3 affects WTAP
protein levels through translation regulation mechanisms
even if, in view of the light shift into polysomal fractions,
it is possible also a contribution from protein stabilization.
In order to further investigate the relationship between
METTL3 and WTAP expression, we analyzed WTAP
levels upon knock down of METTL3 by using two
different lentiviral vectors expressing dox-inducible
shRNA in K562 cells. A non-targeting scramble shRNA
was utilized as control (shSCR). Interestingly, upon
METTL3 downregulation we observed an increase of both
WTAP mRNA and protein levels (Fig. 6a, b). Analysis of
WTAP pre-mRNA levels showed that they did not
increase concomitantly with WTAP mRNA and METTL3
downregulation, indicating that the increase of WTAP
Fig. 6 Knockdown of METTL3 results in an increase of WTAP protein levels. a Western blot analysis of WTAP and METTL3 expression in K562
cells infected with lentivirus expressing dox-inducible shRNAs against METTL3 (shMETTL3_1 and shMETTL3_2). A lentivirus expressing a dox-inducible
scramble shRNA (shSCR) was utilized as control. b qRT-PCR analysis WTAP mRNA and pre-mRNA levels in the same cells. Days of dox induction are
indicated. c Growth curve of K562 infected cells upon dox induction. d qRT-PCR analysis of m6A IP in K562 infected with shSCR, shMETTL3_1 or
shMETTL3_2 after 6 days of dox induction. Data are presented as ±SEM from three independent experiments. *p < 0.05
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mRNA is not due to transcriptional regulation (Fig. 6c).
Altogether these data indicate that both up- and down-
regulation of METTL3 levels result in an increase of
WTAP protein and, therein, that this is not merely due to
protein stabilization by METTL3 interaction. METTL3
depletion by shRNAs resulted in an inhibition of cell
proliferation. However, we did not observe a significant
induction of apoptosis as reported in other AML cell lines
(Supplemental Figure S3). These data indicate that the
increase of WTAP protein upon METTL3 knock down is
not sufficient to promote cell growth. Notably, the increase
of WTAP proteins preceded the arrest in proliferation and
was not observed upon cell cycle arrest of K562 induced by
imatinib, a tyrosine kinase inhibitor that specifically
induces cell cycle arrest and apoptosis in K562 cell (Sup-
plementary Figure S4), indicating that is specifically due to
METTL3 downregulation and not to a general decrease in
cell proliferation. m6A IP followed by qRT-PCR using
primers to amplify the m6A peak region (exon 8) of
fragmented WTAP mRNA was used to analyze the m6A
methylation of WTAP mRNA in K562 AML cells.
Experiments were performed 6 days after dox induction.
As expected, we observed immunoprecipitation of WTAP
exon 8 in control cells and a strong decrease upon
METTL3 knockdown (Fig. 6d). Furthermore, the
enhanced expression of WTAP mRNA coincides with the
loss of m6A modifications. Therein, suggesting that the
observed increase in WTAP it is dependent on the loss of
m6A from its mRNA. We knocked-down the m6A reader
YTHDF2, which destabilizes m6A containing mRNAs, but
we did not observe an increased expression of WTAP
mRNA and protein (Supplemental Figure S5). The iden-
tification of the factor(s) responsible for the modulation of
WTAP expression upon METTL3 knockdown will be
subject of further investigation.
In conclusion, we show that METTL3 protein levels are
important for WTAP protein homeostasis. In particular,
we demonstrate that METTL3 can increase WTAP
expression by at least two independent mechanisms
(Fig. 7). First, increase of METTL3 levels can produce
higher WTAP protein levels, which are independent from
METTL3 catalytic activity and relies on increase WTAP
mRNA translation and protein stabilization. This
mechanism is relevant to increase WTAP expression
concomitantly to the METTL3/METTL14 core complex
and sustain the oncogenic role reported for the m6A
modification complex in leukemia. Second, decrease of
METTL3 levels results in increased WTAP mRNA levels
and, eventually, WTAP protein. However, in the absence
of a functional METTL3 the observed increase of WTAP
protein is not sufficient to promote cell growth. Therein,
these data indicate that the reported oncogenic function
of WTAP is strictly connected to a functional m6A
methylation complex.
Materials and methods
Cell culture and reagents
K562 cell lines were cultured at 37 °C under an atmo-
sphere containing 5% CO2 in RPMI 1640 medium sup-
plemented with 1× penicillin/streptomycin solution, 1× L-
glutamine, and 10% fetal bovine serum (FBS). HeLa cells
were grown in DMEM medium with 10% FBS, 1× L-
glutamine, 1× penicillin–streptomycin and cultured at 37
°C under an atmosphere containing 5% CO2. Doxycycline
(Dox), cycloheximide and Imatinib mesylate were pur-
chased from Sigma-Aldrich.
Fig. 7 A proposed model METTL3 and WTAP interplay in AML.
High levels of METTL3 produces higher WTAP protein levels by
stimulating WTAP mRNA translation and WTAP protein stabilization.
This results in high levels of both the MACOM complex (composed of
WTAP, VIRILIZER, HAKAI, RBM15, and ZC3H13) and the METTL3/
METTL14 methylation complex. This produces high m6A levels and
increase cell proliferation. Conversely, depletion of METTL3 causes low
activity of the METTL3/METTL14 methylation complex, which results in
low m6A level in WTAP mRNA, increased WTAP mRNA stability, and
WTAP protein levels. However, in the absence of the METTL3/METTL14
methylation complex, and eventually high m6A levels, this is not
sufficient to promote cell growth
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Plasmid constructs and cell lines
The METTL3 and WTAP DNA was amplified from
K562 cDNA and cloned Hind III and Not I, and BamH I
and Not I, respectively, in pcDNA3.1 vector with primers
METTL3_HindIII_FW and METTL3_NotI_REV, and
WTAP_BamHI_FW and WTAP_NotI_REV. METTL3
APPA mutant was obtained by reverse PCR with primers
APPA_mettl3_FW and APPA_mettl3_REV. FLAG pep-
tide sequence was introduced upstream the coding
sequence of METTL3 and WTAP constructs by reverse
PCR with primers METTL3_flag_FW and METTL3_-
flag_rev for METTL3 plasmid, and WTAP_flag_FW and
WTAP_flag_rev for WTAP plasmid. FLAG WTAP Δ8
plasmid was obtained by reverse PCR on the plasmid
pcDNA3.1 FLAG WTAP with primers WTAP_m6Ade-
l_iPCR_REV and WTAP_pcDNA_FW. FLAG-METTL3
constructs were subcloned in the enhanced PiggyBac
(ePB) vector ePB-PURO for stable integration25. This
plasmid contains a TET-on system for inducible trans-
gene expression. Helper and transposon plasmids were
electroporated in K562 with Lipofectamine 2000 reagent
(Invitrogen) according to manufacturer instruction.
Selection with 1 μg/ml of puromycin (SIGMA) was initi-
ated 2 days after transfection and maintained until resis-
tant colonies became visible. Induction was obtained with
dox at a concentration of 50 ng/ml. HeLa cells were
transfected with pcDNA 3.1 vectors using Lipofectamine
2000 Reagent (Invitrogen) according to manufacturer
instruction.
For METTL3 downregulation in K562 cells we have
utilized an inducible shRNA expression system based on
the lentiviral vector pLKO-Tet-On26. Inducible constructs
were derived from Mission Lentiviral shRNA clones
(Sigma-Aldrich) TRCN0000289812 (shMETTL3_1),
TRCN0000289814 (shMETTL3_2) and SHC202 TRC2
(Non-Target shRNA Control) as described26. Selection
with 1 μg/ml of puromycin (Sigma-Aldrich) was initiated
2 days after transduction and maintained until resistant
colonies became visible. After selection, shRNAs induc-
tion was obtained with dox at a concentration of 50 ng/
ml.
SiRNAs against YTHDF2 mRNA (Qiagen SI04174534),
METTL3 (Qiagen SI04340749, SI04241265, SI04140038,
SI04317096) and control siRNAs (Qiagen Negative con-
trol 1027281) were transfected in a final concentration of
30 nM using Lipofectamine RNAiMAX (Invitrogen)
according to manufacturer instruction.
Cellular mortality
Cell death was analyzed by flow cytometry (CyAN ADP
DAKO) with propidium iodide (PI) exclusion assay after
staining the cells with 2.5 μg/ml of PI (Sigma-Aldrich, St.
Louis, MO, USA).
Lentivirus packaging and viral transduction
Lentiviral particles were produced by calcium phos-
phate transient transfection of 293T cells, cotransfecting
the specific lentiviral plasmid (pLKO-Tet-On shSCR,
pLKO-Tet-On shMETTL3_1 and pLKO-Tet-On
shMETTL3_2) together with the packaging plasmids
(pLP1 and pLP2) and the envelope plasmid pLP/VSVG
encoding for VSV-G protein. One 150mm dish of
293T cells was transfected for each lentiviral construct.
The calcium phosphate–DNA precipitate was allowed to
stay on the cells for 14–16 h, after which the medium was
replaced with complete media supplemented with 1 mM
sodium butyrate (SIGMA-ALDRICH). The medium was
collected 48 h after transfection, replaced with complete
media supplemented with sodium butyrate 1 mM and
again collected 72 h after transfection. Collected media
were pulled, centrifuged at 1000 rpm for 5 min at room
temperature, filtered through 0.45 μm pore nitrocellulose
filters and then ultracentrifuged at 20,000 rpm for 2 h at 4
°C with SW28 rotor (Beckman Coulter). The supernatant
was then removed while the pellet containing lentiviral
particles was resuspended in 25 μl HBSS buffer (GIBCO
ThermoFisher) and stored at −80 °C.
For viral transduction, 500.000 K562 cells were resus-
pended in 500 μl of serum-free and antibiotic-free media
supplemented with 4 µg/ml Polybrene (SIGMA-
ALDRICH). Cells were then infected with 5 μl of the
lentiviral particles previously resuspended in HBSS buffer.
After 6 h, one volume of medium with serum 2× and
antibiotic 2× was added. 24 h after viral transduction the
medium was replaced with complete medium. 48 h after
viral transduction cells were selected with 1.5 µg/ml of
puromycin (SIGMA-ALDRICH) until resistant colonies
became visible (3–5 days).
Protein stability assay
After 48 h from transient transfection, Hela cells were
treated with 100 μg/ml of cycloheximide for 4 h. We used
non-treated cells as control cells. Cells were than col-
lected and protein fraction was analyzed. Notably, we
analyzed protein levels by western blot using equal
volumes of different samples.
RNA extraction and real-time qRT-PCR analysis
Total RNA was extracted using the Quick RNA mini-
prep kit (Zymo) according to manufacturer instructions.
For mRNA analysis, reverse transcription to cDNA was
performed with the SuperScript VILO cDNA Synthesis
Kit (Life Technologies) according to the manufacturer
instructions. Quantitative real-time PCR was performed
on an Applied Biosystems 7500 Fast Real Time PCR
System. Reactions were performed in triplicate using the
SYBR green dye detection system and analyzed using 7500
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Software v2.0.6 (Applied Biosystems). Relative expression
levels of targets were determined using the comparative
2ΔΔCt method. ActB mRNA was utilized as a reference
(primers: ACTB_hs_FW, ACTB_hs_REV). METTL3 was
analyzed with oligos METTL3 SYBR FW and METTL3
SYBR REV, WTAP with WTAP SYBR FW and WTAP
SYBR REV, FLAG WTAP with FLAG_FW and WTAP
SYBR REV2, endogenous WTAP with WTAP_5′
UTR_FW and WTAP SYBR REV2, endogenous WTAP
with WTAP_5′UTR_FW and WTAP SYBR REV2, WTAP
long isoform with WTAP_long_FW and WTAP_lon-
g_REV, WTAP pre-mRNA with WTAP pre-mRNA FW
and WTAP pre-mRNA REV, HPRT with HPRT SYBR
FW and HPRT SYBR REV, YTHDF2 with YTHDF2 SYBR
FW and YTHDF2 SYBR REV, TAZ with TAZ SYBR FW
and TAZ SYBR REV.
Nuclear/cytoplasmic fractionation
For nucleus to cytoplasm separation approximately 10 ×
106 cells were pelleted and washed with PBS without cal-
cium and magnesium, then they were resuspended in 100 μl
of Buffer A (200mM Tris HCl pH 8, 10mM NaCl, 3mM
MgCl2, 0.1% NP40, 10% glycerol, 0.2mM EDTA, 1mM
DTT) complemented with PIC 1× (Complete, EDTA free,
Roche). Cells were incubated on ice in Buffer A for 10′, and
then centrifuged at 2000 rpm for 5′ at 4 °C. The supernatant
contains the cytoplasmic extract. Buffer A is added to the
pellet containing the nuclei and the resuspended pellet is
centrifuged again for washing. After washing, the pellet is
resuspended in Buffer C (20mM Tris HCl pH 8, 400mM
NaCl, 20% glycerol, 1mM DTT) complemented with PIC
1× (Complete, EDTA free, Roche). The nuclei are subjected
to thermal shock with three cycles of freezing in liquid
nitrogen and thawing at 37 °C. After thermal shock the
extract is centrifuged at 13,000 rpm for 15′ at 4 °C. The
supernatant contains the nuclear extract.
Immunoblot analysis
30 μg of whole cell extract was separated by 10% SDS-
PAGE and electroblotted to nitrocellulose membrane
(Protran, S&S). Immunoblots were incubated with anti-
bodies Anti-FLAGM2 F3165 (Sigma-Aldrich), Anti-WTAP
60188-1-Ig (Proteintech), Anti-METTL3 [EPR18810]
(Abcam), Anti-METTL14 antibody HPA038002 (Sigma
Aldrich), anti-Actinin H-300 sc-15335 (Santa Cruz Bio-
technology), anti-GAPDH sc-25778 (Santa Cruz Bio-
technology), anti-YTHDF2 NBP2-31785 (Novus Biological)
and anti-eIF3A ab86146 (Abcam).
m6A immunoprecipitation
m6A immunoprecipitation was performed as descri-
bed in ref. 27 with a few modifications. Briefly, K562 cells
infected with lentiviral vectors expressing dox-inducible
shRNAs shSCR, shMETTL3_1 and shMETTL3_2 were
induced with dox 50 ng/ml. 6 days after induction total
RNA was extracted and fragmented into ~100 nt long
fragments in Fragmentation Buffer (100 mM Tris–HCl
and 100 mM ZnCl2) for 5′ at 94 °C. Reaction was
immediately blocked with addition of EDTA 50 mM. A
portion of fragmented RNA was kept as input control,
while 50 μg of fragmented RNA were immunoprecipi-
tated in 1 ml of IP Buffer (50 mM Tris–HCl, 750 mM
NaCl and 0.5% Igepal CA-630) complemented with
RNasin (400 U), with 2 μg of m6A-specific antibody
(ab151230, Abcam) or 2 μg of control rabbit IgG (Mil-
lipore) for 2 h of incubation at 4 °C on rotator. Then 20
μl of protein A beads (Invitrogen), saturated with BSA
(SIGMA) 0.5 μg/ml for 2 h, were added and the reaction
mixtures and incubated for 2 h at 4°C on rotator. After
incubation beads were spinned down and washed three
times with IP Buffer. Elution was performed incubating
the beads four times in Elution Buffer (150 mM NaCl,
50 mM Tris–HCl pH 7.5, 1 mM EDTA, 0.1% SDS, 20
mM DTT) for 5′ at 42 °C. Eluted RNA was precipitated
with addition of one-tenth volumes of 3 M sodium
acetate (pH 5.2), and 2.5 volumes of 100% ethanol and
incubated overnight at −80 °C. Precipitated RNA was
then centrifuged at 15,000g for 25′ at 4 °C and pellet
resuspended in 15 μl of RNase-free water. qRT-PCR on
immunoprecipitated RNA was performed with primers
WTAP_long_FW and WTAP_long_REV.
Cross-linking immunoprecipitation
K562 cells stably expressing FLAG-METTL3 or FLAG-
METTL3 APPA were induced with dox 50 ng/ml. 48 h
after induction, cells were cross-linked in PBS at 1500 ×
100 μJ/cm2. Cells were pelleted and washed with PBS
without Calcium and Magnesium, then they were resus-
pended in 1ml of Buffer A (200mM Tris HCl pH 8, 10
mM NaCl, 3 mM MgCl2, 0.1% NP40, 10% glycerol, 0.2
mM EDTA, 1 mM DTT) complemented with PIC 1×
(Complete, EDTA free, Roche) and RNase Inhibitor
(Invitrogen). Cell lysate was incubated on ice for 5′ and
then centrifuged at 2000 rpm for 5′ at 4 °C, the super-
natant contains the cytoplasmic extract. The cytoplasmic
extract was brought to a higher molarity with an equal
RIPA buffer 2× (NaCl 190mM, NP40 0.9%, EDTA 0.8
mM) complemented with DTT 1mM, PIC 1× and RNase
Inhibitor 1×. 30 μl of protein G beads (Invitrogen) were
washed twice with PBS-T buffer (PBS, TWEEN 0.02%)
and then incubated with 7 μg of Anti-FLAG M2 F3165
(Sigma-Aldrich) antibody or 7 μg of mouse IgG as nega-
tive control at room temperature for 1 h. Subsequently,
the beads were washed twice with PBS-T buffer and
incubated at 4 °C on rotator overnight with 1.5 mg of
cellular cytoplasmic extract freshly prepared. Beads were
then washed with HIGH SALT WASH buffer three times
(PBS 10× SIGMA diluted to have a final concentration of
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500mM NaCl, NP-40 0.5%) complemented with PIC 1×
and RNase Inhibitor.
Finally, the immunoprecipitated extract was split for
protein and RNA analysis. 50 μl were denatured in
Laemmli Sample Buffer (Bio-Rad) and DTT 50mM for
protein analysis by Western Blot. The RNA fraction (150
μl) was subjected to reversion of crosslinking with Pro-
teinase K 4mg/ml at 50 °C for 30′. Afterwards, RNA was
isolated for qRT-PCR analysis and normalized on a spike-
in RNA (mouse long non-coding transcript).
CLIP experiments in HeLa cells were performed using
the same protocol 48 h after transient co-transfection with
pcDNA3.1 METTL3 or pcDNA3.1 METTL3 APPA
together with pcDNA3.1 FLAG WTAP Δ8. In this case,
we utilized protein A beads (Invitrogen) and 4 μg of Anti-
METTL3 [EPR18810] (Abcam) antibody or 4 μg rabbit
IgG as negative control (Millipore).
Polysome profiling
Cytoplasm fractionations on sucrose gradients were
performed as follows: 20 × 106 cells were lysed with 500 μl
of lysis buffer (10 mM Tris pH 7.5, 100 mM NaCl, 10 mM
MgCl2, 0.5% Triton X-100, and 0.5% sodium deox-
ycholate) supplemented with 100 mg/ml cycloheximide,
1× PIC (Complete, EDTA free, Roche) and 1× RNase
guard (Thermo Scientific). The lysates were centrifuged
for 5 min at 2000 rpm at 4 °C. The supernatants were
collected and centrifuged on 15–50% sucrose gradient at
37,000 rpm with a SW41 rotor (Beckman) for 2 h at 4 °C.
Fractions were collected with a Bio-logic LP (Biorad). 35
μl of each fraction were pooled together 3 by 3 obtaining
four fractions (Heavy Polysomes, Light Polysomes, 80 S,
Free RNA). 900 μl of Qiazol (Qiagen) was added to each
100 μl fraction and 1 pg of spike in RNA (mouse long
non-coding transcript) was added to each extraction for
further normalization. RNA was extracted using RNeasy
Mini Kit (Qiagen) according to manufacturer instruction.
Data and statistical analysis
Microarray data were downloaded from The Cancer
Genome Atlas (TCGA): TCGA_LAML dataset; and Gene
Expression Omnibus (GEO): GSE12662, GSE19429,
GSE12662, GSE16020, GSE16837, GSE37416, GSE42519,
GSE55849, GSE72642, GSE6054, GSE13899, GSE16836,
GSE60601, GSE66936, GSE72642, and GSE76803 data-
sets. Downloaded data were obtained from the GeneChip
Human Genome U133 Plus 2.0 Array (GPL570) platform
and have been normalized with the DNA-Chip Analyzer
(dChip) software28. The normalization was performed
using an array with median overall intensity chosen as the
baseline array against which other arrays are normalized
at probe intensity level. In this way the brightness of the
arrays was adjusted to comparable level. We utilized the
same software to compute model-based expression values
for each array. LIMMA package was utilized for statistical
analysis of differential expression29. Different p values
obtained for each probe of the same gene were combined
using the Fisher test. p < 0.001 calculated on AML and
CD34 with respect to mature myeloid cells was considered
as statistically significant. MeRIP-Seq (GSM2010455,
GSM2010456), m6A CLIP (GSM1828594, GSM1828596,
GSM2300426) and METTL3 PAR-CLIP (GSM1135006,
GSM1135007) datasets were obtained from GEO.
Data from real time PCR analysis were subjected to the
two-tailed Student’s t test. All values in figures are pre-
sented as the mean ± standard error of mean (SEM) of n
independent experiments. p Values of <0.05 were con-
sidered to be statistically significant and indicated by 1
asterisk in figures.
Oligonucleotides
Cloning:
METTL3_HindIII_FW: CKnockdown of METTL3
results in an increase of WTAP protein levelsGGACAC
GTGGAGC
METTL3_NotI_REV: ATTTGCGGCCGCCTATAAA
TTCTTAGGTTTAGAGAT
WTAP_BamHI_FW: CGCGGATCCATGACCAACG
AAGAACCTCT
WTAP_NotI_REV: ATTTGCGGCCGCTTACAAAAC
TGAACCCTGTACA
APPA_mettl3_FW: CCCGCCGATATTCACATGGAA
CTGCCCTAT
APPA_mettl3_REV: TGGGGCAGCCATCACAACTG
CAAACT
WTAP_flag_FW: GACGACGATAAGACCAACGAA
GAACCTCTTCCCAA
WTAP_flag_FW: GACGACGATAAGACCAACGAA
GAACCTCTTCCCAA
WTAP_flag_REV: ATCCTTGTAATCCATGGATCC
GAGCTCGGTACCAA
METTL3_flag_FW: GACGACGATAAGTCGGACACG
TGGAGCTCTATCC
METTL3_flag_rev: ATCCTTGTAATCCATAAGCTT
AAGTTTAAACGCTAGCCA
WTAP_m6Adel_iPCR_REV: TTCATCCTGACTGCT
TTTAAGCTC
WTAP_pcDNA_FW: TAAGCGGCCGCTCGAGT
qRT-PCR:
ACTB_hs_FW: CGTACCACTGGCATC
ACTB_hs_REV: GTAGTCAGTCAGGTCCCGGC
METTL3 SYBR FW: AAGCAGCTGGACTCTCTGCG
METTL3 SYBR REV: GCACTGGGCTGTCACTACGG
WTAP SYBR FW: TGCGACTAGCAACCAAGGAA
WTAP SYBR REV: ATCTCAGTTGGGCAACGCTC
WTAP SYBR REV2: CTGTGTACTTGCCCTCCAAAG
WTAP_pre-mRNA FW:
TCATTTTGTGATGGATGGCTCT
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WTAP_pre-mRNA REV:
TCAAGTTGTGCAATACGTCCC
WTAP_5′UTR_FW: TTCTGCCTGGAGAGGATTCA
WTAP_long_FW: TCCAGTCATGACCCTCAAGAG
WTAP_long_REV: AGTCCAAGCCATTCTGAACG
HPRT SYBR FW: GCCATCACATTGTAGCCCTCTG
HPRT SYBR REV: TTTATGTCCCCTGTTGAC
TGGTC
FLAG_FW: GATTACAAGGATGACGACGATAAG
YTHDF2_SYBR_FW: GAACCTTACTTGAGTCCAC
AG
YTHDF2_SYBR_REV: GTAGGGCATGGCTGTGT
CAC
TAZ_SYBR_FW: TCACTGTGCTGATCGGGAAG
TAZ_SYBR_REV: TCTCCACAGCCGACTTGTTC
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